

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2002335069 B2**

(54) Title
Plasmapheresis filter device and apparatus for therapeutic apheresis

(51) International Patent Classification(s)
A61M 1/18 (2006.01) **B01D 39/16** (2006.01)
A61M 1/02 (2006.01) **B01D 61/14** (2006.01)
A61M 1/16 (2006.01) **B01D 63/02** (2006.01)
A61M 1/36 (2006.01) **B01D 63/12** (2006.01)
A61M 25/00 (2006.01) **A61M 1/34** (2006.01)

(21) Application No: **2002335069** (22) Date of Filing: **2002.10.15**

(87) WIPO No: **WO03/033054**

(30) Priority Data

(31) Number	(32) Date	(33) Country
09/981,783	2001.10.17	US
10/219,082	2002.08.13	US

(43) Publication Date: **2003.04.28**

(43) Publication Journal Date: **2003.07.03**

(44) Accepted Journal Date: **2008.05.29**

(71) Applicant(s)
Transvivo, Inc.

(72) Inventor(s)
Peters, Harold, W.;Gorsuch, Reynolds, G.;Handley, Harold, H, JR.

(74) Agent / Attorney
Davies Collison Cave, Level 3 303 Coronation Drive Milton Business Centre, QLD, 4064

(56) Related Art
US 5152743
US 5735809

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 April 2003 (24.04.2003)

PCT


(10) International Publication Number
WO 03/033054 A1

- (51) International Patent Classification⁷: A61M 1/16, 1/34, 1/36
- (21) International Application Number: PCT/US02/33173
- (22) International Filing Date: 15 October 2002 (15.10.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/981,783 17 October 2001 (17.10.2001) US
10/219,082 13 August 2002 (13.08.2002) US
- (71) Applicant: TRANSVIVO, INC. [US/US]; 1100 Lincoln Avenue, Suite 108, Napa, CA 94558 (US).
- (72) Inventors: GORSUCH, Reynolds, G.; 1119 State Lane, Yountville, CA 94599 (US). PETERS, Harold, W.; 282 Pebble Creek Court, Martinez, CA 94553 (US). HANDLEY, Harold, H, JR.; 53 Flicker Drive, Novato, CA 94949 (US).
- (74) Agent: HUNT, Dale, C.; KNOBBE, MARTENS, OLSON & BEAR, LLP, 14th Floor, 2040 Main Street, Irvine, CA 92614 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/033054 A1

(54) Title: PLASMAPHERESIS FILTER DEVICE AND APPARATUS FOR THERAPEUTIC APHERESIS



(57) Abstract: A filter device (10) for being implanted in a blood vessel for carrying out in-vivo plasma separation comprises one or more elongated hollow tubes (14, 16) and a plurality of elongated hollow microporous fibers (12), each fiber (12) having a first and second end secured to one or more of the elongated hollow tubes (14, 16) with the interior lumen of each of the fibers communicating with the interior of the one or more of the hollow tubes (14, 16), and wherein the fiber wall has a higher mass density zone adjacent to the outer wall surface and a lower mass density zone adjacent to the inner wall surface. Apparatus for carrying out therapeutic apheresis includes the filter device (10), a multiple lumen catheter (20) secured to the proximal end of the filter device (10) having one or more lumens in fluid communication with the interior of said one or more hollow tubes (14, 16) and a plasma return lumen (52), and therapeutic apheresis apparatus (40) for removing and/or separating selected disease-related components from the separated plasma and means for directing plasma between said catheter and the selective component removal apparatus.

**PLASMAPHERESIS FILTER DEVICE
AND APPARATUS FOR THERAPEUTIC APHERESIS**

Background of the Invention

[0001] In PCT publication WO 01/78805A1 entitled "Specialized Hollow Fiber Membranes for *In-Vivo* Plasmapheresis and Ultrafiltration," there are disclosed elongated hollow microporous fibers having an asymmetrical fiber wall characterized by having a lower mass density adjacent to the inner wall surface extending along the interior lumen of the fiber and a higher mass density adjacent to the outer wall surface. Such a fiber wall morphology and pore structure provide unique characteristics necessary for separating blood plasma and/or plasma water *in-vivo* where continuous extraction of cell-free plasma or ultrafiltered plasma water and its associated toxins is carried out within the blood vessel of a patient or animal. Conventional hollow fibers or filter membranes such as those used in dialysate filter devices are unable to successfully perform *in-vivo*, intravascular plasma separation, becoming clogged within a very short period of time, e.g., minutes, as proteinaceous materials, blood platelets, and other components rapidly occlude the membrane pores. Moreover, conventional dialysate hollow fiber membrane filters do not perform satisfactorily *in-vivo* because of the relatively high flow rate of blood at the exterior fiber surface and relatively low lumen pressure as compared to dialysate filter apparatus conditions in which plasma separation is carried out at relatively low flow rates and high trans-membrane pressures. For example, typical *in-vivo* blood flow within a vena cava is about 2.5 L per minute, while blood flow through typical dialysate filter apparatus is nearly stagnant, e.g., about 0.42 ml per minute per fiber. Intravascular trans-membrane pressure is typically about 50 mm Hg or less, as compared to 100-300 mm Hg used in extracorporeal dialysate filters. Conventional dialysate filter membranes have little structural strength which, although acceptable in an encapsulated dialysate filter environment external to the body, are not suitable for intravascular use.

[0002] In the field of medicine, the term "therapeutic apheresis" refers to techniques for treating diseases using the patient's blood. Current medical practice extracts whole blood from the patient and, as a first stage, separates the plasma from the blood *ex-vivo* by centrifugal or membrane separation, and in a second stage treats the separated plasma by various techniques. The treated plasma and blood are recombined *ex-vivo* and returned to the patient. In the simplest procedure the separated plasma including the pathogenic macromolecules is discarded and substitution fluids such as fresh frozen plasma and albumen solution are re-infused to the patient.

[0003] In all of the aforesaid and currently practiced therapeutic apheresis procedures, whole blood must be removed from the body and processed in two *ex-vivo* stages. However, removal and treatment of whole blood has major disadvantages. Whole blood removal results in

the necessity to heparinize or anticoagulate the patient to minimize clotting in the *ex-vivo* circuit and apparatus. Such treatment is counter-indicated in most surgical patients and deleterious to others due to consequential damage to blood components and the removal of vital blood components unrelated to the therapy. Removing and treating whole blood *ex-vivo* dictates that the procedure be a "batch" or intermittent process with attendant loss of efficiency and confinement of the patient to a clinical setting where support systems and machinery are available. Removal of whole blood also exposes the patient to contamination by viral and/or bacterial infection from nosocomial sources, and removal of erythrocytes, platelets and other large cellular blood components exposes them to risk of damage due to mechanical and chemical exposure to non-biocompatible surfaces of *ex-vivo* apparatus.

Summary of the Invention

[0004] The present invention relates to a filter device for being implanted in a blood vessel for carrying out *in-vivo* plasma separation comprising:

one or more elongated hollow tubes and a plurality of elongated microporous fibers having an interior lumen extending along the length thereof, each fiber having a first and second end secured to one or more of said elongated hollow tubes, wherein the interior lumen of each of the fibers communicates with the interior of one or more of the hollow tubes, and wherein the fiber wall morphology of each of the elongated microporous fibers is asymmetrical between the inner wall surface extending along the interior fiber lumen and the outer wall surface, said fiber wall having a higher mass density zone adjacent to the outer wall surface and a lower mass density zone adjacent to the inner wall surface, said higher mass density zone having a smaller average nominal pore size than the average nominal pore size in the lower mass density zone.

[0004a] In a preferred embodiment, the device comprises a pair of elongated hollow tubes joined along their length with a first end of each of the hollow fibers secured to and communicating with the interior of one of the hollow tubes, and the second end of each of the fibers secured to and communicating with the interior of the other hollow tube.

[0004b] A plasma or plasma water extraction catheter includes a multiple lumen catheter, preferably a triple lumen catheter, secured to a proximal end of the one or more hollow tubes and communicating with the tube interior for directing blood plasma or

plasma water passing through the fiber wall and into the fiber lumen to extracorporeal treatment or collection apparatus or equipment.

[0005] The present invention also relates to methods and apparatus for carrying out therapeutic apheresis using the filter device of the invention. In the present invention, plasma, not whole blood, is removed from the patient in a first stage of therapeutic apheresis. Plasma separation is performed *in-vivo* by a plasma separation filter placed in an appropriate vein and the separated plasma is pumped to a therapeutic apheresis selective component removal system for separating and removing selected disease-related plasma components or plasma containing such components such as toxins, antibodies, proteins, bacteria, and/or viruses. After the appropriate disease-related plasma component is extracted by the therapeutic apheresis apparatus, the processed plasma, and if desired fresh plasma, is pumped to the patient. The system may also include fluid control piping and cooperating pumps for directing plasma between system components. The system may include backflush components comprising piping, backflush pump and source of backflush fluid selectively directed to the filter device for a duration and flow rate sufficient to substantially cleanse filter pores. In a preferred embodiment, operation of the system is controlled by a microprocessor/controller.

Brief Description of the Drawings

Various embodiments of filter device, apparatus and methods according to the invention will now be described by way of example only, with reference to the accompanying drawings in which:

[0006] Fig. 1 is a top view of a preferred embodiment of the filter device having a pair of elongated substantially parallel hollow tubes joined together along their length, showing distal and proximal end segments;

[0007] Fig. 2 is an enlarged sectional view of the filter device of Fig. 1 along the lines A-A showing a single elongated hollow fiber secured to the hollow tubes;

[0008] Fig. 3 is an enlarged side view of a portion of a filter device of the type illustrated in Fig. 1 showing four elongated hollow fibers secured along the hollow tubes;

[0009] Figs. 4 and 5 are sectional and side views of another filter device embodiment;

- 3A -

[0010] Fig. 6 is a sectional view of a triple lumen catheter illustrating the catheter interior;

[0011] Fig. 7 is a scanning electron microscopy (SEM) image of a cross-section of a typical elongated hollow fiber used in the filter device at 100 μm magnification showing the asymmetrical wall structure between the inner and outer fiber wall surface;

[0012] Fig. 8 is a SEM cross-section of a fiber of Fig. 7 at a magnification of 400 μm .

[0013] Fig. 9 is a schematic illustration of a preferred embodiment of apparatus for carrying out therapeutic apheresis;

[0014] Fig. 10 schematically illustrates one embodiment of therapeutic apheresis apparatus using plasma exchange; and

[0015] Fig. 11 schematically illustrates a therapeutic apheresis apparatus embodiment using double, cascade filtration.

Detailed Description of the Preferred Embodiments

[0016] In the preferred embodiment illustrated in Figs. 1-3, a pair of elongated hollow tubes are joined side-by-side lengthwise to form the core of the filter device. The two elongated hollow core tubes 14 and 16 terminate at a distal end with a distal end plug or cap 13 formed of a material that seals the open tube ends. The tubes and end cap may be made of any suitable biocompatible material, for example, medical grade extruded urethane tubes. Other biocompatible materials include synthetic rubbers, polycarbonate, polyethylene, polypropylene, nylon, etc. The elongated hollow tubes may be secured together using suitable bonding material 18, adhesive compositions, etc., for example, a UV curable adhesive applied along the length between the two tubes. The length and diameter of the filter device may be selected to accommodate the vessel or

25

vein in which it is to be implanted. Accordingly, the diameter and length of the one or more elongated hollow tubes forming the central core of the filter device are selected. A suitable tube length is between about 15 cm and about 25 cm, and preferably between about 18 cm and about 22 cm. Where a pair of core tubes is used as shown in the preferred embodiment, an outer diameter of each tube of between about 1 mm and about 3 mm is suitable. A detectable marker component 31, e.g., a radio opaque material may also be bonded to the device, for example, in bonding material 18 extending along the length of the tubes to assist in implanting and/or monitoring the device especially during insertion and removal.

[0017] The elongated hollow microporous fibers used in the filter device are the asymmetrical wall fibers disclosed in WO 01/78805. The morphology of the fiber walls is asymmetrical between the inner fiber lumen and the outer fiber wall which is in direct contact with the blood flowing in the vasculature in which the device is implanted. The filtration performance of such a device is a function of the filter surface of the exposed fibers whereby consideration is given to use larger diameter fibers and to maximize the number of fibers. Thus, it is desirable to use as many individual fibers along the hollow core tubes of the filter device as is practical while maintaining separation of the individual fibers to provide for fluid flow therebetween, and to maximize the amount of outer fiber surface exposed to blood flowing along the length of the filter device. Moreover, the fibers are secured along the length of the hollow tubes in such a manner as to form a fluid flow space between the fibers and the tubes. Again, however, the length of the filter device as well as the overall cross-sectional dimension are tailored or dictated by the blood vessel in which the device is to be used so as to avoid substantial interference with blood flow through the vessel while at the same time be efficient to achieve the intended flow rate of separated plasma.

[0018] In a preferred embodiment, the ends of each of the fibers are offset longitudinally relative to one another as illustrated in Figs. 1-3. As shown, elongated hollow fiber 12 has a first end 21 secured in first elongated hollow tube 14 and second end 23 secured in second hollow tube 16. In the specific device illustrated, the longitudinal spacing between the first and second ends of each fiber is a three-hole or three-fiber offset, e.g., about 0.5 cm. However, with intervals between the adjacent fiber ends of between about 0.1 cm and about 1.0 cm, offsets between first and second fiber ends may be between about 0.3 cm and about 3.0 cm, by way of example. With such offsets between first and second fiber ends, a straight line extending between the ends of a fiber forms an acute angle with an elongated axis of either or both of the elongated hollow tubes, and whereby the fibers also extend lengthwise between their ends along an angle other than 90° relative to the axes of the elongated hollow tubes. The acute angle preferably is between about 45° and about 85°. However, other fiber angles including 90° are not precluded and may be used where desired. In another preferred embodiment shown in Fig. 1, the proximal and

distal fibers 11 and 15 located at each end of the filter device are filled with polyurethane or other biocompatible synthetic resin composition. These solid fibers at the ends of the row of fibers protect the adjacent hollow fibers from potential damage caused by mechanical stress during catheter insertion and removal.

[0019] In an example of assembly of a filter device, the elongated hollow core tubes 14 and 16 are joined as previously described and holes are drilled at the desired spacing along each of the two tubes. The holes may be drilled along opposite sides of the two tubes, and preferably are spaced at regular intervals of between about 0.1 cm and about 1.0 cm, and more preferably between 0.1 cm and about 0.3 cm. In a device as illustrated in Figs. 1-3, 6 fibers/cm are used and the interval or spacing between fiber ends along each of the tubes is approximately 1.66 mm. However, other practicable fiber spacing may be used, for example, between about 4 and about 8 fibers/cm and preferably between 5 and 7 fibers/cm of the length of the hollow tubes. The fibers may be secured in the spaced holes by any suitable method. For example, a first fiber end is inserted in a first hole in one of the tubes, the tubes are rotated 180°, and a second end of the fiber inserted in a first hole in the other tube. The procedure is repeated until all fiber ends are inserted in the holes along the two joined tubes. A wire or other elongated member may be inserted along the interior of each of the core tubes during assembly to provide a uniform limit or stop for the fiber ends along the respective hollow tube interior passageways. The fibers are bonded to the tubes and the joints between the fibers and the tubes sealed using a suitable adhesive or potting compound and the wires are removed. In the specific example of a filter device shown in Fig. 1, 118 active hollow fibers and 2 filled end fibers are spaced at 6 fibers/cm along 20.4 cm of the tubes. Each fiber is about 1.5 mm long.

[0020] Figs. 4 and 5 illustrate an alternative embodiment in which fibers are positioned on two sides of the filter device. Fibers 32 and 34 extend at opposite sides of the device whereby first and second ends of each of the fibers are secured along two rows along each of the tubes. As shown in Figs. 2-5, the fibers are arched to form a space between the fibers and the elongated tubes. In Figs. 2 and 3, a space 25 is formed by the arched fibers, and in Figs. 4 and 5, two spaces 27 and 29 are formed by the arched fibers on both sides of the filter device. The length of the fibers may be selected to accommodate the desired filter surface, as well as the desired cross-sectional dimension of the filter device as previously discussed. Suitable fiber lengths are between about 1 mm and about 4 mm to provide sufficient space between the arched fibers and the hollow tubes without distorting the fibers which could cause undesirable strains along the fiber walls or otherwise compromise fiber performance. The location of first and second fiber ends of the embodiment illustrated in Figs. 4 and 5 may be as described for the embodiment of Figs. 2 and 3.

[0021] The fiber wall structure of the elongated microporous fibers is asymmetrical between the inner wall surface extending along the interior fiber lumen and the outer fiber wall surface exposed to blood in the vessel in which the filter device is implanted. The fiber wall at or adjacent to the outer wall surface has a higher mass density than the mass density adjacent to or at the inner wall surface. The mass density is a function of the average nominal pore size. Such asymmetric fiber wall morphology is illustrated in Figs. 7 and 8, Fig 7 showing a scanning electron microscopy (SEM) image of a cross-section of the fiber at 100 μm magnification. Fig. 8 shows a portion of the Fig. 7 fiber wall cross-section at a magnification of 400 μm . It will be observed that the structure of the fiber from the outer surface to the lumen is a continuous change in mass density whereby the pore size gradually changes between these fiber wall surfaces. However, it is convenient to describe the different mass density as sections or zones of the wall area having an average nominal pore size or average pore diameter, each zone having a different average nominal pore size. The walls may be characterized by two or more zones, for example 2, 3, or 4 or more mass density zones. The hollow fibers shown in Figs. 7 and 8 are also shown and described in the aforesaid publication WO 01/78805. In the fibers, the outer surface of the membrane, zone 1, has the highest mass density characterized by smaller average pore diameters. The outer zone forms the fiber interface with the permeate blood flow by determining filtration characteristics including the composition and components of separated plasma and controlling fiber membrane performance. Thus, zone 1 is the principle filtration portion of the fiber wall for controlling the trans-membrane flux (TMF) for excluding even the smallest cells in the blood, the platelets, having a diameter of about 1 μm . Nominal average pore diameters in zone 1 are between about 0.3 μm and about 1 μm , and preferably range from about 0.4 μm to about 0.8 μm . A preferred filtration sizing has a cutoff of about 0.6 μm to about 0.8 μm . Zones 2 and 3 are designed to decrease the flow path tortuosity and maintain the structural integrity required of the fiber exposed to physical conditions within the body. Pore size distribution in these zones ranges gradually from about 0.8 μm to about 1.2 μm and from about 1.2 μm to about 2.0 μm , respectively. Zone 2, having some flux-controlling pores, is principally to provide structural strength to the fiber as well as acting as a conduit for exudate flow to zone 3, also providing structure and enlarged pores for reducing the hydraulic resistance and providing a fluid conduit to the fiber lumen. The interior zones have little filtration function. Zone 4, representing the largest area having relatively large voids and pore diameters with little solid structure, has the primary function of a major reduction of hydraulic resistance through the membrane and defines the fiber inner lumen surface. Nominal average pore diameters in this lowest mass density zone are between about 1 μm and about 60 μm , and preferably between about 2 μm and about 6 μm . A typical fiber as shown has an OD of about 650 μm , an ID of about 250 μm and a wall thickness of about 250 μm . However, such dimensions are

by way of example only. The fiber wall morphology, voids and pores may be further observed in WO 01/78805, with figures illustrating the structures at magnifications of 1,000 μm and 5,000 μm .

[0022] The elongated microporous fibers used in the filter device may be produced using biocompatible polymers including those produced from polyurethane, polypropylene, polysulfone (polyethersulfone), polycarbonate, nylon, polyimide, as well as other synthetic resins known to those skilled in the art. A preferred polymer is polysulfone, and more preferably a polyethersulfone/polyethylene oxide copolymer with a polyethylene glycol solvent or a polysulfone modified with polyethylene oxide-polyethylene glycol copolymer. Such polysulfone fibers are produced in the presence of polymer dopes, core fluids, and coagulation fluids using processes including membrane spinning methods which achieve the desired product. Examples of such additive materials used in the polymerization process, spinning process and/or fiber membrane production include polyvinyl pyrrolidone, N-methyl pyrrolidone, dimethyl acetamide, dimethyl sulfoxide, and mixtures of two or more such materials. Such polysulfone fibers have been found to have the least detrimental characteristics that influence protein membrane interaction such as crystallinity, ionic groups, hydrogen bonding groups and hydrophobic sites. Specific methods for producing the aforesaid polymers and fibers are known to those skilled in the art and disclosed, for example, in PCT Publication WO 90/04609.

[0023] The filter device is used for carrying out *in-vivo* plasmapheresis in combination with a multiple lumen catheter, preferably a triple lumen catheter as illustrated in Fig. 6. The catheter is of a suitable length to provide for implanting or installing the filter device into the appropriate vessel of the patient, e.g., the inferior vena cava, between the diaphragm and the iliac junction via the femoral vein, jugular vein or subclavian vein. The catheter 20 may be secured to the proximal end 17 of the filter device 10 by a suitable method, e.g., using a suitable adhesive and an injection-molded connector 19. The catheter 20 has an access lumen 26 which is in open fluid communication with the interior of elongated hollow tubes 14 and 16 of the filter device. Return lumen 22 is occluded or blocked off at the distal end of the catheter 20, and is provided with one or more ports through the catheter wall near the distal end of the catheter whereby treated plasma may be returned to the patient. Backflush lumen 24 is also in open fluid communication with the interior of the hollow tubes 14 and 16 through which periodic backflush fluid is directed for preventing occlusion of the hollow fiber membrane caused by blood components. Such backflush procedure and apparatus are discussed in detail in publication WO 02/053210 A2. The proximal end of the triple lumen catheter is secured to tubing components of a plasma separation system. The system includes plasma treatment apparatus for removing and/or separating selected plasma components and a fluid control assembly for directing plasma from the catheter to the treatment apparatus and return to the patient. The fluid control assembly also

includes a pump for pumping plasma from the catheter to the treatment apparatus, a source of backflush fluid and a pump for pumping backflush fluid to the backflush lumen of the catheter. The fluid control apparatus also includes a microprocessor/controller for operating the pumps and controlling plasma flow rates and backflush fluid pressures, and backflush pumping intervals. The plasma treatment apparatus may be a single or multiple stage dialysate filter assembly or cascade membrane filters, absorbent cartridges, specialized adsorbent columns, chemical process or extraction assembly, or combinations, known to those skilled in the art.

[0024] Examples of medical applications for which the filter device described herein may be used include the following: therapeutic apheresis applications including plasma exchange, cascade protein separation and cascade protein removal or modification; fluid management application for congestive heart failure both acute and chronic; tissue engineering applications including online generation of media for bioreactor from xenogenic, allogenic, and autogenic sources; continuous renal replacement therapy (CRRT) for both acute and chronic kidney failure; edema prevention therapies for MODS (multiple organ dysfunction syndrome); cytokine removal or modification in therapy for septic shock or SIRS (systemic inflammatory response syndrome); plasma extraction from peritoneal ascites; intermittent hemodialysis (IHD) or hemodiafiltration; and ARDS (acute respiratory distress syndrome) therapy by reduction of pulmonary edema and physiological pulmonary dead space. Additional uses for the filter device of the present invention will be evident to those skilled in the art.

[0025] A preferred embodiment of an apparatus using the aforesaid filter device for carrying out therapeutic apheresis is schematically illustrated in Fig. 9. The apparatus includes a filter device 10, a triple lumen catheter 20, a therapeutic apheresis selective component removal apparatus 40, a fluid control assembly including tubing and pumps, and a microprocessor/controller 30. Veins suitable for implanting the filter include the superior or inferior vena cava or the subclavian vein. In the drawing, the filter device 10 is shown implanted in the inferior vena cava 50. A triple lumen catheter 20 is secured to the proximal end of the filter with connector 19. Triple lumen catheter 20 is in fluid communication with the interior of the filter device with the three catheter lumens connected to tubing for directing outgoing plasma, return plasma, and backflush fluid. Referring also to Figs. 1, 2 and 6, plasma separated from whole blood through the microporous fibers 12 of the filter device are directed through access lumen 26 and first tubing 51 to selective component apparatus 40. Plasma is separated from whole blood within the blood vessel in which the filter device is inserted using trans-membrane pressure (TMP) supplied by access pump or first pump 54, a positive displacement volumetric pump that operates to regulate pressure and control trans-membrane pressure and plasma volume removal rate.

[0026] Plasma from the filter device is pumped to the therapeutic apheresis selective component removal apparatus 40 for selectively removing disease-related components such as toxins, antibodies, proteins, pathogens including bacteria, virus, etc., and other disease-related substances desired to be removed. Plasma components and solutes removed from the treated plasma are directed to a container 44. An effluent pump 42 is optional and may be advantageously used for assisting in controlling the rate of disease components removed by providing controlled trans-membrane pressure across filter membranes of the selective component removal apparatus. Plasma is returned to the patient via tubing 43 at a rate controlled by pump 36. The tubing 43 is in fluid communication with plasma return tube 52 which is connected to plasma return lumen 22 of triple lumen catheter 20 (Fig. 5).

[0027] Examples of selective component removal apparatus used for therapeutic apheresis include plasma exchange components, centrifugal or membrane-separation filters, such as disclosed in U.S. Patent No. 5,605,627, cascade or multiple filtration membranes and columns, cartridges having components for absorbing (adsorbing) proteins and specific disease-related components, and activated charcoal cartridges. Other examples of useful selective component removal components include specialized columns utilizing materials such as cross-linked polyvinyl alcohol gel beads or microporous cellulose beads for removing specific amino acid ligands and antibodies. Further examples of selective component removal apparatus are chemical process systems for specialized uses such as heparin precipitation, plasma cyrofiltration, and salt-amino acid co-precipitation, and the like. Chemical process apparatus for effectively neutralizing disease related components in the plasma may also be used. These and other selective component removal apparatus and technologies are described in Therapeutic Apheresis, Official Journal of the International Society for Apheresis, Vol. 1-6, Blackwell Science Inc., "Present Status of Apheresis Technologies", e.g. Vol. 1, No. 2, May, 1997, pp. 135-146. Combinations of two or more of any of the aforesaid apparatus may also be used.

[0028] Fig. 10 illustrates a plasma exchange apparatus 45 for separating plasma components and for delivering fresh plasma from supply source 49. The plasma exchange rate may be selected as a function of the plasma removal rate by proportioning the rate of operation of access pump 34 to effluent pump 42, as shown in Fig. 9.

[0029] Fig. 11 schematically illustrates an example of selective component removal apparatus showing a cascade filter comprising a first stage filter 46 and a second stage filter 47. A pump 48 is used for directing fluid plasma from the first stage filter to the second stage filter. A source of make-up plasma liquid 49 may be used, if desired, for introducing substitution fluids such as fresh plasma which is combined with the treated plasma to be returned to the patient via tubing 41 and 43. Container 44 receives and collects discarded plasma fluid containing disease-

related components, such as toxins, etc. as previously described. In a single stage treatment apparatus, the use of a make-up plasma liquid is also optional as is effluent pump 42 shown in Fig. 1 and cooperating with selective component removal apparatus 40 for directing fluid and components to be discarded. Again, following treatment in selective component removal apparatus 40, plasma is returned to the patient via piping 43 and positive displacement pump 36 to plasma return tube 52 which is in fluid communication with plasma return lumen 22 of triple lumen catheter 20.

[0030] An apparatus using cartridges or columns for absorbing or adsorbing disease-related components may also be used for treating separated plasma. Such apparatus may be configured like or similar to that illustrated in Figs. 10 and 11 in which the columns shown incorporate absorbing or adsorbing filters comprising materials capable of absorbing selected disease-related components such as discussed herein. Again, such an apparatus may include a source of fresh plasma to be directed to the patient, if desired.

[0031] A preferred apparatus shown in Fig. 9 includes backflush fluid reservoir 37, backflush pump 38 and backflush tube 53 communicating with a backflush lumen of the triple lumen catheter. Backflush pump 38 is selectively and periodically operated to provide backflush fluid flow for substantially cleansing the pores of the fiber membrane of the filter device. Such a backflush cycle is preferably operated at high trans-membrane pressure and low volume and at relatively short injection times for backflushing whereby the membrane pores are temporarily expanded and flushed to dislodge adhered proteins, thereby restoring pore integrity and density of the virtual filter area for improved performance after each backflush cycle.

[0032] Fluid control of plasma within the apparatus may be controlled using a microprocessor/controller operatively communicating with the positive displacement volumetric pumps for controlling trans-membrane pressure in the filter device and selective component removal apparatus, plasma removal rate, plasma return rate and backflush pressure and rate. Such fluid control and management may be selected, tailored or designed for slow, continuous acute fluid removal. For example, operation of the system may be used for controlling plasma extraction rate from blood to achieve removal of 1-2 L of plasma water over a 24-hour period. The fluid control assembly may also include volume sensors, pressure sensors, blood leak detectors and air detectors connected to the piping and reservoirs as desired. As illustrated in Fig. 9, the microprocessor/controller 30 is operatively connected to the pumps. Similarly, the microprocessor/controller operates for controlling backflush pump 38 and plasma is returned at a selected rate by controlling pump 36. The microprocessor/controller may be programmed for flow rates designed to a the prescribed patient therapy.

[0033] Examples of diseases and disorders for which therapeutic apheresis may be used and the pathogenic substances removed using the methods and apparatus of the invention include those described in Therapeutic Apherisis, Vol. 1, No. 2, 1997. The list is not intended to be exhaustive, and other diseases and substances may also be treated.

5 Moreover, the methods and apparatus described herein may also be used in drug treatment, for example in drug overdose cases, where one or more toxic substances in the blood stream may be removed using the aforesaid methods and apparatus. These as well as other advantages will be evident to those skilled in the art.

[0034] Throughout this specification and the claims which follow, unless the

10 context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

[0035] The reference in this specification to any prior publication (or

15 information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A filter device for being implanted in a blood vessel for carrying out *in-vivo* plasma separation comprising:

5 one or more elongated hollow tubes and a plurality of elongated microporous fibers having an interior lumen extending along the length thereof, each fiber having a first and second end secured to one or more of said elongated hollow tubes, wherein the interior lumen of each of the fibers communicates with the interior of one or more of the hollow tubes, and wherein the fiber wall morphology of each of the elongated microporous fibers is asymmetrical between
10 the inner wall surface extending along the interior fiber lumen and the outer wall surface, said fiber wall having a higher mass density zone adjacent to the outer wall surface and a lower mass density zone adjacent to the inner wall surface, said higher mass density zone having a smaller average nominal pore size than the average nominal pore size in the lower mass density zone.

15 2. A filter device of Claim 1 comprising one or more first and one or more second elongated hollow tubes extending substantially parallel along the length thereof, and wherein a first end of each of said elongated microporous fibers is secured to a first hollow tube and a second end of each of said fibers is secured to a second hollow tube whereby the interior fiber lumen of each fiber communicates with the interior of a first and
20 a second hollow tube.

3. A filter device of Claim 2 comprising two of said elongated hollow tubes, each of said tubes having a plurality of holes spaced apart along a substantial portion of the length thereof, each hole receiving a first or a second end of an elongated microporous fiber.

25 4. A filter device of Claim 2 or 3 wherein the first and second ends of said elongated microporous fibers are secured to said first and second elongated hollow tubes in generally straight rows along the side of each of said tubes.

5. A filter device of Claim 4 wherein the first hollow tube extends along a first axis and the second hollow tube extends along a second axis substantially parallel with
30 said first axis, and wherein the first ends of said elongated microporous fibers are secured to said first hollow tube along a generally straight first row, and the second ends of said

elongated microporous fibers are secured to said second hollow tube along a generally straight second row substantially parallel with said first row.

6. A filter device of Claim 5 wherein the distance between said first and second rows is greater than the distance between said first and second axes.

5 7. A filter device of Claim 5 or 6 wherein the first end of each elongated microporous fiber is offset longitudinally from the second end of each said fiber along the length of said elongated hollow tubes whereby a straight line extending through the first and second end of a fiber forms an acute angle with one of said axes.

8. A filter device of Claim 7 wherein the length of each hollow tube is
10 between about 10 cm and about 25 cm, wherein the length of each elongated microporous fiber is between about 1 mm and about 4 mm, wherein the space between adjacent fibers is between about 0.1 cm and about 0.3 cm, and wherein said acute angle is between about 45° and about 85°.

9. A filter device of Claim 7 or 8 having between 4 and 8 fibers/cm of the
15 length of said hollow tubes.

10. A filter device of any one of Claims 1 to 9 wherein the fiber wall structure comprises a continuous change in mass density between the inner and outer surfaces of the fiber.

11. A filter device of Claim 10 wherein a lower mass density zone is
20 characterized by a nominal average pore diameter of between about 1 μm and about 60 μm .

12. A filter device of Claim 11 wherein the nominal average pore diameter in a lower mass density zone is between about 2 μm and about 6 μm .

13. A filter device of any one of Claims 10 to 12 wherein a higher mass density
25 zone is characterized by a nominal average pore diameter of between about 0.3 μm and about 1 μm .

14. A filter device of Claim 13 wherein the nominal average pore diameter in a higher mass density zone is between about 0.4 μm and about 0.8 μm .

15. A filter device substantially as herein described with reference to the
30 accompanying drawings.

16. Apparatus for carrying out therapeutic apheresis comprising:

an implantable filter device of any one of the preceding claims;

a triple lumen catheter secured to the proximal end of the filter device having one or more lumens in fluid communication with the interior of said one or more hollow tubes and a plasma return lumen; and

5 therapeutic apheresis apparatus for removing and/or separating selected disease-related components from the separated plasma and tubing for directing plasma between said catheter and the selective component removal apparatus.

17. Apparatus of Claim 16 wherein said triple lumen catheter comprises a first lumen and a second lumen in fluid communication with the interior of said one or more
10 hollow tubes and a third lumen comprising said plasma return lumen.

18. Apparatus of Claim 16 or 17 including:

a fluid control assembly comprising first tubing in fluid communication with said first lumen of said catheter and a first fluid pump cooperating therewith for directing plasma from said filter device, second tubing in fluid communication
15 with said second lumen of said catheter and a second pump cooperating therewith for directing backflush fluid into said filter device, and third tubing in fluid communication with said third lumen of said catheter for directing plasma from the therapeutic apheresis apparatus to a patient; and

control apparatus operatively communicating with said first and second
20 pumps for controlling the operation thereof, respectively.

19. Apparatus of Claim 18 including a third pump cooperating with said third tubing and in control connection with said control apparatus.

20. Apparatus of Claim 18 or 19 including a source of backflush fluid cooperating with said second tubing.

25 21. Apparatus of any one of Claims 18 to 20 wherein said controller comprises a microprocessor-controller including software programmed for operating said apparatus.

22. A method of carrying out therapeutic apheresis comprising:
securing a triple lumen catheter having a filter device of any one of Claims
1 to 15 on the proximal end thereof in the superior or inferior vena cava or
30 subclavian vein of a patient, said filter device capable of separating plasma from whole blood *in-vivo* at pressures and flow rates therein;

2002335069 08 May 2008

- 15 -

separating plasma from whole blood *in-vivo* and directing the separated plasma through a first lumen of said triple lumen catheter to a therapeutic apheresis selective component removal apparatus;

5 carrying out therapeutic apheresis by separating and removing and/or neutralizing selected disease-related components comprising toxins, antibodies, proteins, bacteria, viruses, and/or combinations of two or more thereof from the plasma; and

10 returning treated plasma to the patient via a second lumen of said triple lumen catheter.




FIG. 1




FIG. 2




FIG. 4




FIG. 6




FIG. 3




FIG. 5





FIG. 7



FIG. 8






FIG. 11




FIG. 10